<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A randomized placebo-controlled study has been carried out in 3 Moscow hospitals </plain></SENT>
<SENT sid="1" pm="."><plain>A sample included 90 patients who survived hemispheric <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> caused by pathology in the internal carotid artery 72 h before the treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Forty-five patients were given standard (basic) therapy and 45 patients received adjuvant batroxobin intravenously by 1,0 ml (10BU) drops on day 1, 3 and 5 and by 0,5 ml (5BU) drops on day 7 and 9 after admitting in a hospital </plain></SENT>
<SENT sid="3" pm="."><plain>Assessment of the patients' state was conducted before the treatment, on day 3, 6 and 15 </plain></SENT>
<SENT sid="4" pm="."><plain>The European <z:hpo ids='HP_0001297'>Stroke</z:hpo> Scale was used to measure severity of clinical symptoms </plain></SENT>
<SENT sid="5" pm="."><plain>The results suggest efficacy of batroxobin the use of which provides rapid good results, especially improvement in <z:hpo ids='HP_0100022'>movement disorders</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The use of this drug is accompanied by defibrinating effect </plain></SENT>
<SENT sid="7" pm="."><plain>The drug is well tolerated </plain></SENT>
</text></document>